Management Team


HK Pharmaceuticals is led by individuals with experience in building highly successful biotechnology companies.

Brief biographies of key members of management are listed below:

Hubert Köster, Ph.D., Founder, Chairman and CEO
Dr. Köster is an entrepreneur known and trusted by the international investment community as the founder and leader of several successful biotechnology companies. He is a renowned biochemist and a pioneer in the areas of genetic engineering, prokaryotic transcription, chemical synthesis of DNA, and DNA analysis, with further scientific expertise in biochemistry, molecular biology and mass spectrometry. Prior to founding HK Pharmaceuticals, Dr. Köster founded Sequenom, Inc., a now publicly traded company (NASDAQ:SQNM) and industry leading tool provider in the field of genomics. He served as Sequenom’s President, Chief Executive Officer and Board Member from 1994 through 2000, managing the Company from inception through IPO.

Under Dr. Köster’s leadership, Sequenom raised approximately $70 million in private equity from 1994 through 1999, and in February 2000 accessed the public markets raising $157 million in a heavily oversubscribed IPO, one of the largest in the biotechnology industry’s history. Prior to founding Sequenom, Dr. Köster co-founded and led research efforts at MilliGen/Biosearch, the biotech division of Millipore Corporation. In 1981, he founded Biosyntech GmbH, the first biotech company in Germany and served on its Board of Directors and Scientific Advisory Board. In 1978, he was appointed tenured professor of organic chemistry and biochemistry at Hamburg University.

Dr. Köster currently holds more than 40 patents and has authored more than 110 scientific publications. He received his Ph.D. in Chemistry from Hamburg University, completed doctoral research at the Max Planck Institute for Experimental Medicine in Göttingen, and completed post-doctoral research work at the Max Planck Institute for Virus Research in Tubing.

Daniel P. Little, Ph.D., Founding President
Dr. Little was appointed as HK Pharmaceuticals’ President upon its becoming operational in November 2001. He is a leader in the field of mass spectrometry of biological molecules. Prior to joining HK Pharmaceuticals, Dr. Little served for six years at Sequenom, Inc., most recently as Vice President and General Manager of East Coast Operations. As one of its first six employees, his scientific accomplishments were a cornerstone to the development of Sequenom’s MassArray technology, which is today widely recognized as the leading industrial-scale genotyping methodology.

In his later roles in the Business Development Group and in establishing and managing the Company’s East Coast (Boston, MA) Operations, Dr. Little was the key driver in successfully introducing Sequenom’s technology into the commercial marketplace, and accounted for approximately 35% of its worldwide revenues in years 2000 – 2001. Dr. Little received his Ph.D. degree in Chemistry from Cornell University. He currently holds eleven issued U.S. patents and has authored more than 30 peer-reviewed scientific publications.

Ping Yip, Ph.D., Director of Bioinformatics
Dr. Yip is an expert in protein modeling and structural analysis, the interactions of proteins with small molecules, database design, and computationally intensive signal processing of complex data. Prior to joining HK Pharmaceuticals, he most recently was the Director of Bioinformatics at Sequenom, Inc., where he led various bioinformatics functions, including key software development for the company’s genetic analysis platform and internal target discovery efforts. Prior to this, he was a Senior Principal Scientist at Molecular Simulation Inc. (now Accelrys, Inc.). Dr. Yip holds a Ph.D. in Theoretical Physics from the University of Chicago.

Suhaib Siddiqi, Ph.D., Director of Chemistry
Dr. Siddiqi has over 16 years of post-graduate experience in synthetic organic, medicinal and computational chemistry, with extensive expertise in the drug discovery process. Dr. Siddiqi was one of the earliest employees at Inspire Pharmaceuticals, Inc., where he designed and synthesized drug candidates to enhance the clinical management of disease involving the immune system. Several of these drug candidates are now in clinical trials.

He also designed and synthesized novel agonists and antagonists for G-protein coupled receptors to target chronic pulmonary diseases. He was instrumental in establishing Inspire’s Information Technology function, including computer-aided drug design. Prior to Inspire, he was at the National Institutes of Health, where he designed and synthesized therapeutic agents for central nervous system, cardiac and kidney diseases. Dr. Siddiqi completed his Ph.D. in Synthetic Organic Chemistry at the Technical University of Vienna in Austria.